Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Receivables (2022 - 2025)

Coeptis Therapeutics Holdings has reported Receivables over the past 4 years, most recently at $5.1 million for Q3 2025.

  • Quarterly results put Receivables at $5.1 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $5.1 million (changed N/A YoY), and the annual figure for FY2024 was $2.1 million, up 5287.65%.
  • Receivables for Q3 2025 was $5.1 million at Coeptis Therapeutics Holdings, up from $30000.0 in the prior quarter.
  • Over the last five years, Receivables for COEPW hit a ceiling of $5.1 million in Q3 2025 and a floor of -$2.0 million in Q4 2024.
  • Median Receivables over the past 4 years was $30000.0 (2025), compared with a mean of $466995.3.
  • Biggest five-year swings in Receivables: soared 382.7% in 2023 and later crashed 5231.1% in 2024.
  • Coeptis Therapeutics Holdings' Receivables stood at $8075.0 in 2022, then skyrocketed by 382.7% to $38978.0 in 2023, then crashed by 5231.1% to -$2.0 million in 2024, then surged by 354.12% to $5.1 million in 2025.
  • The last three reported values for Receivables were $5.1 million (Q3 2025), $30000.0 (Q2 2025), and -$2.0 million (Q4 2024) per Business Quant data.